多价特兰胺酸 (TXA) 和胺基衍生物用于血清蛋白酶抑制
Tanmaye Nallan Chakravarthula1,2, Rodrigo Santillan-Rodriguez1, Ziqian Zeng1,2
1Department of Emergency Medicine, Indiana UniversitySchool of Medicine, Indiana University, Indianapolis, Indiana 46202, United States.
ACS pharmacology & translational science
|June 26, 2025
概括
研究人员开发了新的异构生物分子,以向血液凝固酶. 优化的链接长度增强了对等离子素和组织等离子素激活剂的抑制,为出血和凝血障碍提供了潜在的治疗策略.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 血液凝固和纤维素分解是由血清蛋白酶调节的关键静血过程.
- 血静失衡可能导致严重出血或血栓状况,需要治疗干预.
研究的目的:
- 为了合成和评估结合本扎米丁和松酸 (TXA) 的异构生物分子,以抑制血液静止中的关键蛋白酶.
- 研究不同链接长度对抑制剂对等离子素,血栓素和组织等离子素激活剂 (tPA) 疗效的影响.
主要方法:
- 用不同长度的dPEG连接器 (dPEG4-dPEG36) 合成异质双价分子.
- 使用可溶性基质进行酶分析,以确定抑制常量 (Ki) 和IC50值.
- 对被光标记的纤维素凝块的抑制作用的评估,以评估纤维素分解潜力.
主要成果:
- 抑制剂对等离子素和tPA的有效性随着链接长度超过活性和氨酸结合位点的分离而增加,这归因于多价值结合.
- 同类多元的TXA通过统计重新结合证明了对等离子体的强有力的竞争性抑制 (Ki = 2.5 ± 1.8 μM).
- 纤维素凝块上的IC50值提供了对Kringle结合抑制对纤维素分解的影响的见解.
结论:
- 在异质双价抑制剂中定制链接长度可以优化抑制参与血静的血清蛋白酶的抑制.
- 多价值结合和统计重结合是增强蛋白酶抑制的有效策略.
- 这些发现有助于开发用于止血性疾病的新疗法.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
924
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
924
Venous Thrombosis III: Interprofessional Care
28
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
28
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
Combined Effects of Drugs: Synergism
4.8K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
4.8K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
655
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
655
Masking and Demasking Agents
2.7K
EDTA titrations may necessitate masking and demasking agents to temporarily protect a particular metal ion in a mixture from the EDTA reaction. These agents facilitate the sequential analysis of the metal ions by forming stable complexes with some—but not all—metal ions during certain steps.
There are many masking agents, such as cyanide, fluoride, triethanolamine, thiourea, and 2,3-bis(sulfanyl)propan-1-ol (formerly 2,3-dimercapto-1-propanol), with the masking agent chosen based on...
There are many masking agents, such as cyanide, fluoride, triethanolamine, thiourea, and 2,3-bis(sulfanyl)propan-1-ol (formerly 2,3-dimercapto-1-propanol), with the masking agent chosen based on...
2.7K


